Insider Millions and a Looming Deadline: Gerresheimer’s Rebound Hinges on Trust

Executives and shareholders load up on €9.7M in shares; stock jumps 59% in a month but annual report delay and debt restructuring test rally sustainability.

Gerresheimer executives and major shareholders have been loading up on the company’s shares with unusual zeal, buying nearly €9.7 million worth of stock in the latest round of reportable insider trades – more than nine times the volume seen at Rheinmetall over the same period. The flurry of insider purchases, which tops the German league table for such transactions, has been accompanied by a fresh increase in the stake held by investment vehicle Active Ownership, which now owns well over 15% of the speciality packaging group.

Yet the stock’s recent surge – up 59% in the past month and roughly 75% from its February trough of €15.57 – paints only half the picture. Over twelve months the shares remain 55% in the red, and the company is still grappling with an unresolved audited annual report that was pulled in February amid internal investigations into certain business practices. That document is now expected to land in June, a milestone that will test whether the rally is built on solid ground.

Creditor breathing room buys time for clean-up

To avoid a funding crunch while the internal probe runs its course, Gerresheimer secured extended maturity dates from its key lenders earlier this spring. Banks and Schuldschein holders granted waivers stretching into late summer, giving interim management the flexibility to finish its review without triggering a liquidity emergency. The support has been a critical safety net, allowing the company to focus on the balance sheet repair that investors are watching closely.

Alongside the accounting work, the group is pressing ahead with a strategic divestiture: the sale of its US-based Centor unit, which produces plastic packaging for the retail sector. Proceeds from the disposal are earmarked to pare down net financial debt, which had risen after a spate of acquisitions and capital spending. The exit fits a broader pivot toward higher-margin drug-delivery systems and specialist pharmaceutical packaging – the same arena where Gerresheimer is already marketing its Duma Combi-Container, a ready-to-use solution that integrates a separate compartment for traditional package inserts and is winning over pharma clients looking for immediate deployment over experimental technologies.

Technicals, insider conviction and two Junes to watch

The buying frenzy has driven the stock within striking distance of its 200-day moving average, currently pegged at €27.83. A clean break above that level would be interpreted by chartists as a major trend reversal. The share price last traded at €27.32, leaving less than 2% upside to the threshold.

But the sustainability of the rally will ultimately hinge on the credibility of the numbers. The June release of the audited financials will be the first real test: the market will scrutinise whether the announced corrections stay within the range of earlier estimates. Only after that report is published can Gerresheimer set a new date for its annual general meeting and restore a semblance of normal governance.

Management has promised to deliver further details on the current business trajectory in June 2026, raising questions about how much visibility the company itself has over the medium term. For now, the €9.7 million bet placed by insiders suggests those closest to the firm see value at these levels – but the audited paper that lands this June will determine whether the rally has any legs.